OpenAI Rejects Apple Trade Secret Theft Claims 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Add as a preferred source on Google
SAN DIEGO, March 07, 2018 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its year end 2017 financial results on Monday, March 19, 2018 after the close of the U.S. financial markets. Company management will host a conference call and webcast on Monday, March 19, 2018 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the results and provide a corporate update.
Interested parties may access the call by dialing toll-free (844) 358-9116 from the US or (209) 905-5951 internationally and using conference ID 3697758.
The press release and links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr’s clinical stage ATYR1923 (iMod.Fc) program is an agonist of the Resokine pathway designed to temper immune engagement in interstitial lung diseases. aTyr’s preclinical research stage ORCA program, targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com.
Contact:
Mark Johnson
Sr. Director, Investor Relations
[email protected]
858-223-1163
